People with musical anhedonia have reduced connectivity between brain areas associated with reward and sound processing, a new study reports.
Inflammation appears to reduce reward response in females. Reduced activity in the brain's reward system is a key component of anhedonia, the loss of enjoyment in activities, a core feature of depression. The findings may explain why depression is more prevalent in women than in men.
Patients with schizophrenia, but not those with social anhedonia, exhibited deficits in real-life social network size. Those with schizophrenia and those with social anhedonia had reversals functional connectivity to one another. People with schizophrenia showed decreased segregation and functional connectivity in brain areas associated with social behaviors, while those with social anhedonia had an increase in connectivity and segregation.
Rats susceptible to anhedonia have more serotonin neurons in the ventral dorsal raphe nucleus. However, activating neurons in the central amygdala reduced the serotonin signaling and lowered the effects of social stress.
Researchers have identified an exceptional mouse model of schizophrenia. The study identified a mutant mouse lacking the Schnurri-2 protein (Shn-2 KO) that exhibits behavioral deficits and other brain features consistent with schizophrenia.
Researchers find high level of inflammation markers in the blood of people with depression. The research indicates persistent inflammation affects brain areas associated with the more stubborn symptoms of depression.
Using fMRI to examine the brains of children while resting, researchers discover anhedonia is associated with hyperconnectivity between the cingulo-opercular network and ventral striatum.
Study links anhedonia, or the loss of pleasure, to the early onset of frontotemporal dementia. Neuroimaging revealed symptoms of anhedonia were marked by atrophy in the frontal and striatal brain areas of those with FTD.
Stanford researchers have identified five new categories of specific symptoms and brain area activation that can be applied to the diagnosis of anxiety and depression in a more specific manner.
A new study reveals a brain region that contributes to anhedonia, the loss of pleasure, in those with depression. The study also shows how ketamine acts on this brain region, explaining why the drug appears to be so effective at treating anhedonia.
Ezogabine, a drug that opens up the KCNQ2/3 type potassium channel, significantly improved symptoms of depression and anhedonia.
In depressed people, the habenula functions abnormally, a new study reports.